452 related articles for article (PubMed ID: 16862524)
1. Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program.
Favaloro EJ; Bonar R; Kershaw G; Sioufi J; Baker R; Hertzberg M; Street A; Marsden K
Semin Thromb Hemost; 2006 Jul; 32(5):505-13. PubMed ID: 16862524
[TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis of von Willebrand disorder: use of multiple functional assays reduces diagnostic error rates.
Favaloro EJ; Bonar R; Kershaw G; Sioufi J; Thom J; Baker R; Hertzberg M; Street A; Lloyd J; Marsden K;
Lab Hematol; 2005; 11(2):91-7. PubMed ID: 16024332
[TBL] [Abstract][Full Text] [Related]
3. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel.
Favaloro EJ; Smith J; Petinos P; Hertzberg M; Koutts J
Thromb Haemost; 1999 Oct; 82(4):1276-82. PubMed ID: 10544913
[TBL] [Abstract][Full Text] [Related]
4. Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process.
Favaloro EJ; Bonar R; Kershaw G; Sioufi J; Hertzberg M; Street A; Lloyd J; Marsden K;
Haemophilia; 2004 May; 10(3):232-42. PubMed ID: 15086320
[TBL] [Abstract][Full Text] [Related]
5. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD.
Favaloro EJ; Bonar R; Meiring M; Street A; Marsden K;
Thromb Haemost; 2007 Aug; 98(2):346-58. PubMed ID: 17721617
[TBL] [Abstract][Full Text] [Related]
6. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification.
Favaloro EJ; Bonar R; Marsden K
Clin Lab Sci; 2008; 21(3):178-83. PubMed ID: 18678140
[TBL] [Abstract][Full Text] [Related]
7. Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program.
Favaloro EJ; Bonar R
Semin Thromb Hemost; 2007 Apr; 33(3):235-42. PubMed ID: 17427057
[TBL] [Abstract][Full Text] [Related]
8. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
9. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
10. von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia).
Penas N; Pérez-Rodríguez A; Torea JH; Lourés E; Noya MS; López-Fernández MF; Batlle J
Am J Hematol; 2005 Nov; 80(3):188-96. PubMed ID: 16247740
[TBL] [Abstract][Full Text] [Related]
11. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult.
Favaloro EJ
Semin Thromb Hemost; 2007 Nov; 33(8):727-44. PubMed ID: 18175279
[TBL] [Abstract][Full Text] [Related]
12. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program.
Hayes TE; Brandt JT; Chandler WL; Eby CS; Kottke-Marchant K; Krishnan J; Lefkowitz JB; Olson JD; Rund CR; Van Cott EM; Cunningham MT
Semin Thromb Hemost; 2006 Jul; 32(5):499-504. PubMed ID: 16862523
[TBL] [Abstract][Full Text] [Related]
13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
14. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation.
Meijer P; Haverkate F
Semin Thromb Hemost; 2006 Jul; 32(5):485-91. PubMed ID: 16862521
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of von Willebrand disease in Australia.
Favaloro EJ; Bonar R; Favaloro J; Koutts J
Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198
[TBL] [Abstract][Full Text] [Related]
16. Laboratory diagnosis of von Willebrand disorder. Current practice in the southern hemisphere.
Favaloro EJ; Bonar R; Sioufi J; Hertzberg M; Street A; Lloyd J; Marsden K;
Am J Clin Pathol; 2003 Jun; 119(6):882-93. PubMed ID: 12817437
[TBL] [Abstract][Full Text] [Related]
17. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
18. Evaluating Performance of Contemporary and Historical von Willebrand Factor (VWF) Assays in the Laboratory Identification of von Willebrand Disease (VWD): The Australasian Experience.
Favaloro EJ; Dean E; Arunachalam S
Semin Thromb Hemost; 2022 Sep; 48(6):711-731. PubMed ID: 35803263
[TBL] [Abstract][Full Text] [Related]
19. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
[TBL] [Abstract][Full Text] [Related]
20. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
